RCS - LungLife AI, INC - Participation in National Cancer Institute’s EDRN

LungLife AIAnnouncement

17/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221017:nRSQ0057Da&default-theme=true

RNS Number : 0057D  LungLife AI, INC  17 October 2022

 

LungLife AI, Inc.

(the "Company" or "LungLife")

 

LungLife to participate in the US National Cancer Institute's Early Detection
Research Network

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, announces that based on the strength of its technology it will be one
of two industry partners to participate in the Boston University ("BU")
-University of California Los Angeles ("UCLA") Lung Cancer Biomarker
Development Laboratory of the US National Cancer Institute's Early Detection
Research Network ("EDRN").

 

The EDRN is a division of the US National Cancer Institute, the federal
government's principal agency for cancer research and training. The EDRN's
mission is to discover, develop, and validate new biomarkers and medical
imaging technologies to detect early-stage cancers, and to translate them into
clinical tests. It is comprised of over 300 investigators from academic
institutions and industry partners working collaboratively to bring new
diagnostic biomarkers to clinical use.

 

LungLife's clinical laboratory will operate as a Biomarker Reference
Laboratory, processing blood samples from the participating academic centres
at UCLA and BU where the LungLB® test will be combined with imaging to assist
their early detection research, as well as validate combined test performance
in patients with indeterminate lung nodules. It is expected the blood samples
will be collected over a number of years with progress and results presented
to EDRN members at annual meetings, representing the first independent study
of LungLB®. These activities are independent of LungLife's ongoing pivotal
validation study and do not impact on the progress of this study.

 

The work of the EDRN closely aligns with LungLife's mission to increase the
early detection of lung cancer and will provide further clinical evidence for
the LungLB® technology as well as widen awareness of our technology with
leading US investigators. It also affords LungLife the potential to offer
novel cell-based diagnostic biomarkers discovered at UCLA and BU to physicians
from its clinical laboratory, thereby potentially expanding its lung cancer
testing capabilities.

 

Paul Pagano, CEO for LungLife said: "We are excited that LungLife will
participate in such a prestigious national programme aimed at bringing early
detection technology to the clinic, and we are delighted to work with UCLA and
BU, two leading medical research institutions with teams that have been
pushing the field forward to make important biomarkers available to patients."

 

Denise Aberle, MD, Professor of Radiology and Bioengineering, Vice Chair for
Research, Department of Radiological Sciences at UCLA, EDRN Investigator said:
"Lung cancer remains the deadliest cancer because most people are diagnosed in
later stages after developing symptoms - the ability to detect lung cancer in
early stages could have a profound effect on patients' outcomes. Cell-based
biomarkers have considerable potential for early cancer detection. When
combined with imaging markers using artificial intelligence/radiomics analysis
of computed tomography, combined imaging and cell-based approaches could
substantially shift the diagnosis of lung cancer to early stages when it is
most curable.

 

"We look forward to collaborating on this grant to evaluate novel imaging and
cell-based biomarkers in patients with intermediate-risk indeterminate lung
nodules, which are the most diagnostically challenging nodules to evaluate and
represent a critical unmet need in early lung cancer detection."

 

BU's press release can be found at: https://www.bumc.bu.edu/busm/news-events/
(https://www.bumc.bu.edu/busm/news-events/)

 

For further information please contact:

 

 LungLife AI, Inc.                                 www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                  Via Walbrook PR
 David Anderson, CFO

 Walbrook PR Limited                                Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                   (mailto:LungLifeAI@walbrookpr.com)
 Paul McManus / Alice Woodings / Phillip Marriage  Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

 

About LungLife AI

 

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQZLFFLBLFFBB